Keep up with the latest news on HFpEF
08-29-2021 | ESC 2021 | Conference coverage | News
Empagliflozin has broad beneficial effect on HFpEF outcomes
Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.
08-27-2021 | ESC 2021 | Conference coverage | News
EMPEROR-Preserved: A win for empagliflozin in HFpEF
Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.
Experts discuss the clinical implications of EMPEROR-Preserved
08-29-2021 | ESC 2021 | Conference coverage | Video
EMPEROR-Preserved: The implications for primary care
Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.
Stay informed with Medicine Matters
Get the latest developments in diabetes delivered straight to your inbox